VINCENT JAMES L 4

4 · ALNYLAM PHARMACEUTICALS, INC. · Filed Jun 15, 2010

Form 4

Period: 2010-06-11

Director

Transactions

Sale
Common Stock
2010-06-14$16.10/sh−5,000$80,482→ 10,000 total
Exercise/Conversion
Common Stock
2010-06-14$7.02/sh+2,900$20,358→ 12,900 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2010-06-14−5,000→ 45,000 total
Exercise: $7.02From: 2006-07-12Exp: 2015-07-12→ Common Stock (5,000 underlying)
Exercise/Conversion
Common Stock
2010-06-11$7.02/sh+15,000$105,300→ 25,000 total
Sale
Common Stock
2010-06-11$15.95/sh−15,000$239,250→ 10,000 total
Exercise/Conversion
Common Stock
2010-06-14$7.02/sh+10,000$70,200→ 20,000 total
Exercise/Conversion
Common Stock
2010-06-14$7.02/sh+5,000$35,100→ 15,000 total
Sale
Common Stock
2010-06-14$16.05/sh−2,900$46,548→ 10,000 total
Sale
Common Stock
2010-06-14$16.10/sh−10,000$160,963→ 10,000 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2010-06-11−15,000→ 60,000 total
Exercise: $7.02From: 2006-07-12Exp: 2015-07-12→ Common Stock (15,000 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2010-06-14−10,000→ 50,000 total
Exercise: $7.02From: 2006-07-12Exp: 2015-07-12→ Common Stock (10,000 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2010-06-14−2,900→ 42,100 total
Exercise: $7.02From: 2006-07-12Exp: 2015-07-12→ Common Stock (2,900 underlying)

Footnotes (1)

[F1]The stock option vested as to one third of the shares on each of the first, second and third anniversaries of the grant date.

Documents

1 file